UroToday - Clinical Follow Up

March 20, 2010

March 2010

Home

Parenchyma

Clinical Follow Up

Traditionally, most patients with sporadic RCC are followed every 6 months or yearly with a history and physical examination (H&P), liver function studies, serum chemistry (including alkaline phosphatase), CXR, and abdominal cross-sectional imaging.
However, contemporary series from M.D. Anderson and the Cleveland Clinic suggest that recurrence is generally a rare event for T1 and T2 lesions. In addition, pulmonary metastasis are most common and usually can be diagnosed by chest radiography. Stage-specific follow-up guidelines have been proposed as follows.
- TI: H&P, serum chemistry, and CXR yearly for 5 years
- T2: H&P, serum chemistry, and CXR every 6 months; abdominal CT scan at 2 and 5 years for 5 years
- T3: H&P, serum chemistry, and CXR at 3 months, then every 6 months; abdominal CT scan at 2 and 5 years

References

Bostwick DG, Eble JN: Diagnosis and classification of renal cell carcinoma. Urol Clin N Am 26:627-635, 1999.
Caddeddu JA, Ono Y, Clayman RV, et al: Laparoscopic nephrectomy for renal cell cancer: Evaluation of efficacy and safety: A multicenter experience. Urology 52:773-777, 1998.
Levy DA, Slaton JW, Swanson DA, Dinney CP: Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 15:1163-1167, 1998.
Montie JM: Lymphadenectomy for renal cell carcinoma. Semin Urol 7:181-185, 1989.
Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996.
Novick AC: Renal-sparing surgery for renal cell carcinoma. Urol Clin North Am 20:277-282, 1993.
Sagalowsky AI, Kadesky KT, Ewalt DM, Kennedy TJ: Factors influencing adrenal metastasis in renal cell carcinoma. J Urol 151:1181-1184, 1994.
Skinner DG, Pritchett RT, Lieskovsky G, Boyd SD, Stiles QR: Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. Ann Surg 210:387-394, 1989.
Sufrin G, Cashon S, Golio A, Murphy GP: Paraneoplastic and serologic syndromes of renal adenocarcinoma. Semin Urol 7:158-171, 1989.
Yang JC, Topalian SL, Parkinson D, et al: Randomized comparison of high-dose and low-dose intravenous interleukin 2 for the therapy of metastatic renal cell carcinoma: An interim report. J Clin Oncol 12:1572-1576, 1994.